ClinicalTrials.gg

Program

Abiraterone Acetate

Also written as “Abiraterone acetate”, “Abiraterone” and “abiraterone acetate”.

Its studies are mostly in Prostatic Neoplasms · Neoplasm Metastasis · Breast Neoplasms · Bulbo-Spinal Atrophy, X-Linked · Prostatic Neoplasms, Castration-Resistant, led by 8 companies.

Furthest: phase 4, since Mar 27, 201553 company-led studies, 7 open or runningNext primary completion: Dec 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Johnson & Johnson414 open or runningphase 4since Mar 27, 2015May 11, 2007none ahead
Jiangsu HengRui Medicine32 open or runningphase 2since Apr 25, 2021Apr 25, 2021Dec 2026phase 2 · NCT06568094
Sun Pharmaceutical Industries31 open or runningphase 2since Mar 25, 2016Mar 25, 2016Dec 31, 2027phase 2 · NCT05422911
Sanofi20 open or runningphase 4since Jun 26, 2015Jan 4, 2012none ahead
Boryung Pharmaceutical10 open or runningphase 1since May 12, 2021May 12, 2021none ahead
Sino Biopharmaceutical10 open or runningphase 3since Aug 11, 2019Aug 11, 2019none ahead
Sumitomo Pharma10 open or runningphase 1since Dec 7, 2020Dec 7, 2020none ahead
zentiva-k-s10 open or runningphase 1since Mar 2, 2020Mar 2, 2020none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 39 studies since May 11, 2007.

  1. Jun 26, 2015Phase 4 study in Prostate Cancer MetastaticSanofi · NCT02485691 · 255 enrolled · Austria, Belgium, Czechia and more
  2. Mar 25, 2016Sun Pharmaceutical Industries’ first study: phase 2 study in Prostatic NeoplasmsNew to Sun Pharmaceutical IndustriesSun Pharmaceutical Industries · NCT02737332 · 53 enrolled · United States
  3. Oct 31, 2016Phase 2 study in Prostatic NeoplasmsSun Pharmaceutical Industries · NCT02962284 · 20 enrolled
  4. Nov 19, 2018Phase 3 study in Prostatic Neoplasms, Castration-ResistantJohnson & Johnson · NCT03748641 · 765 enrolled · United States, Argentina, Australia and more
  5. Aug 11, 2019Sino Biopharmaceutical’s first study: phase 3 study in Metastatic Castration Resistant Prostate CancerNew to Sino BiopharmaceuticalSino Biopharmaceutical · NCT04056754 · 268 enrolled · China
  6. Mar 2, 2020zentiva-k-s’ first study: phase 1 study in PharmacokineticsNew to zentiva-k-szentiva-k-s · NCT04295161 · 33 enrolled · United Kingdom
  7. Jul 31, 2020Phase 3 study in Prostatic NeoplasmsJohnson & Johnson · NCT04497844 · 696 enrolled · United States, Argentina, Australia and more
  8. Oct 5, 2020Phase 1 study in Prostatic NeoplasmsJohnson & Johnson · NCT04577833 · 136 enrolled · United States, Belgium, France and more
  9. Dec 7, 2020Sumitomo Pharma’s first study: phase 1 study in Metastatic Castration-Resistant Prostate CancerNew to Sumitomo PharmaSumitomo Pharma · NCT04666129 · 48 enrolled · United States
  10. Apr 25, 2021Jiangsu HengRui Medicine’s first study: phase 2 study in Metastatic Castration-resistant Prostate Cancer (mCRPC)New to Jiangsu HengRui MedicineJiangsu HengRui Medicine · NCT04862091 · 69 enrolled · China
  11. May 12, 2021Boryung Pharmaceutical’s first study: phase 1 study in Prostatic NeoplasmsNew to Boryung PharmaceuticalBoryung Pharmaceutical · NCT04889651 · 40 enrolled · Korea, Republic of
  12. Jun 9, 2022Phase 2 study in Neoplasm MetastasisSun Pharmaceutical Industries · NCT05422911 · 192 planned · United States
  13. Oct 13, 2023Phase 1 study in Neoplasm MetastasisJiangsu HengRui Medicine · NCT06099990 · 660 planned
  14. Aug 21, 2024Phase 2 study in Prostatic NeoplasmsJiangsu HengRui Medicine · NCT06568094 · 100 planned · China

Ahead

  1. Dec 2026Primary completion: phase 2 study in Prostatic NeoplasmsJiangsu HengRui Medicine · NCT06568094
  2. Dec 31, 2027Primary completion: phase 2 study in Neoplasm MetastasisSun Pharmaceutical Industries · NCT05422911
  3. Dec 2028Primary completion: phase 1 study in Neoplasm MetastasisJiangsu HengRui Medicine · NCT06099990

TargetBeta

CYP17A1 →read by rule
“Cytochrome P450 17A1 inhibitor”ChEMBL 37, by rule

Studies

All 53 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT06568094Prostatic Neoplasms · China2RecruitingJiangsu HengRui MedicineDec 2026100
NCT06099990Neoplasm Metastasis1Not yet recruitingJiangsu HengRui MedicineDec 2028660
NCT05422911Neoplasm Metastasis · United States2RecruitingSun Pharmaceutical IndustriesDec 31, 2027192
NCT04889651Prostatic Neoplasms · Korea, Republic of1CompletedBoryung PharmaceuticalJun 8, 202140
NCT04862091Metastatic Castration-resistant Prostate Cancer (mCRPC) · China2CompletedJiangsu HengRui MedicineOct 21, 202169
NCT04666129Metastatic Castration-Resistant Prostate Cancer · United States1CompletedSumitomo PharmaMay 28, 202448
NCT04577833Prostatic Neoplasms · United States, Belgium, France and more1Active, not recruitingJohnson & JohnsonOct 15, 2021136
NCT04497844Prostatic Neoplasms · United States, Argentina, Australia and more3Active, not recruitingJohnson & JohnsonJan 7, 2025696
NCT04295161Pharmacokinetics · United Kingdom1Completedzentiva-k-sNov 8, 201933
NCT04056754Metastatic Castration Resistant Prostate Cancer · China3CompletedSino BiopharmaceuticalMar 14, 2018268
NCT03748641Prostatic Neoplasms, Castration-Resistant · United States, Argentina, Australia and more3Active, not recruitingJohnson & JohnsonOct 8, 2021765
NCT02962284Prostatic Neoplasms2CompletedSun Pharmaceutical IndustriesMar 201820
NCT02737332Prostatic Neoplasms · United States2CompletedSun Pharmaceutical IndustriesFeb 27, 201753
NCT02485691Prostate Cancer Metastatic · Austria, Belgium, Czechia and more4CompletedSanofiMar 27, 2019255
NCT02405858Metastatic Castration-Resistant Prostate Cancer · Japan4CompletedJohnson & JohnsonDec 31, 201751
NCT02230046Healthy · United States1CompletedJohnson & JohnsonNov 2014102
NCT02217566Prostatic Neoplasms · Brazil2CompletedJohnson & JohnsonOct 26, 201846
NCT02123758Prostatic Neoplasms · United States, Canada, Netherlands and more1Active, not recruitingJohnson & JohnsonJun 27, 201657
NCT02001571Prostatic Neoplasms · United States1CompletedJohnson & JohnsonApr 201024
NCT01873001Healthy Volunteers · Belgium1CompletedJohnson & JohnsonJul 201316
NCT01795703Prostatic Neoplasms · Japan2CompletedJohnson & JohnsonOct 201447
NCT01756638Prostatic Neoplasms · Japan2CompletedJohnson & JohnsonOct 17, 201448
NCT01715285Prostatic Neoplasms · Argentina, Australia, Belgium and more3CompletedJohnson & JohnsonOct 31, 20161,209
NCT01715259Renal Insufficiency · United States1CompletedJohnson & JohnsonJan 201016
NCT01798628Healthy Volunteers1CompletedJohnson & JohnsonOct 200936
NCT01695135Prostatic Neoplasms · China3CompletedJohnson & JohnsonJun 20, 2014214
NCT01685983Prostatic Neoplasms · Korea, Republic of, Taiwan2CompletedJohnson & JohnsonJan 24, 201382
NCT01678573Healthy · China1CompletedJohnson & JohnsonSep 201215
NCT01664728Prostatic Neoplasms · United Kingdom1CompletedJohnson & JohnsonFeb 200954
NCT01640093Healthy Participants · United States1CompletedJohnson & JohnsonJul 201232
NCT01591122Prostatic Neoplasms · China, Malaysia, Russian Federation and more3CompletedJohnson & JohnsonDec 31, 2016313
NCT01655147Healthy · Belgium1CompletedJohnson & JohnsonMar 201219
NCT01517802Breast Neoplasms · United States, Australia, Belgium and more3CompletedJohnson & JohnsonApr 22, 202132
NCT01575587Pharmacology · United States1CompletedJohnson & JohnsonMay 201251
NCT01588782Healthy Volunteers · Belgium1CompletedJohnson & JohnsonFeb 201220
NCT01511536Prostatic Neoplasms · United States, France, United Kingdom2CompletedSanofiJul 201438
NCT01495910Congenital adrenal hyperplasia due to 21 hydroxylase deficiency · United States1CompletedJohnson & JohnsonFeb 20136
NCT01424930Prostatic Neoplasms · Canada2CompletedJohnson & JohnsonApr 201325
NCT01381874Breast Neoplasms · United States, Belgium, France and more2CompletedJohnson & JohnsonJul 28, 2014297
NCT01362764Healthy Volunteers1CompletedJohnson & JohnsonJun 201130
NCT01314118Prostatic Neoplasms · United States2CompletedJohnson & JohnsonDec 24, 2013131
NCT01186484Prostatic Neoplasms · Japan1CompletedJohnson & JohnsonOct 2, 201427
NCT01017939Prostatic Neoplasms · United States, Canada1CompletedJohnson & JohnsonJun 201034
NCT00924469Prostatic Neoplasms · United States2CompletedJohnson & JohnsonFeb 201258
NCT00910754Prostatic Neoplasms · United States, Canada1CompletedJohnson & JohnsonNov 200933
NCT00887198Prostatic Neoplasms · United States, Australia, Belgium and more3CompletedJohnson & JohnsonMar 31, 20141,088
NCT00638690Prostatic Neoplasms · United States, Australia, Austria and more3CompletedJohnson & JohnsonAug 20101,195
NCT00600535Prostatic Neoplasms · United States, United Kingdom1CompletedJohnson & JohnsonMar 201231
NCT00544440Prostatic Neoplasms · United States2CompletedJohnson & JohnsonAug 201257
NCT00485303Prostatic Neoplasms · United States, United Kingdom2CompletedJohnson & JohnsonOct 201158
NCT00474383Prostatic Neoplasms · United States, United Kingdom2CompletedJohnson & JohnsonAug 201147
NCT00473746Prostatic Neoplasms · United States2CompletedJohnson & JohnsonDec 201266
NCT00473512Prostatic Neoplasms · United Kingdom2CompletedJohnson & JohnsonNov 200854

How it is read

Names in the registry

  • “Abiraterone acetate”, 24 entries
  • “Abiraterone”, 10 entries
  • “Abiraterone Acetate”, 5 entries
  • “abiraterone acetate”, 2 entries
  • “Abiraterone acetate (Treatment B)”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.